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Abstract
The literature on pharmacogenomics as a tool to support antidepressant precision is 
burgeoning. Recently, a more active role has been argued for pharmacists in phar-
macogenomic testing, with both pharmacists and family physicians perceiving 
pharmacist- led testing as a valuable method by which to scale this innovation for 
depression treatment. In this prospective, single- blind randomized controlled design, 
we evaluated the impact of pharmacogenomics guided versus standard antidepressant 
treatment of depression and anxiety, implemented in three large community pharma-
cies. Participants were 213 outpatients diagnosed with major depressive disorder and/
or generalized anxiety disorder, randomized to receive pharmacogenomics guided 
(n = 105) or standard antidepressant treatment (n = 108); participants were blinded to 
the study. Patient reported outcomes of depression, anxiety, disability, and treatment 
satisfaction were assessed at months 0, 1, 3, and 6. Hypotheses were investigated 
using mixed effect models on the full data. All clinical outcomes improved signifi-
cantly. The primary outcome (depression) and two secondary outcomes (generalized 
anxiety and disability) exhibited significant time by group interactions indicating that 
they improved for participants who received pharmacogenomics guided treatment 
more so than they did for participants who received standard treatment. Treatment 
satisfaction improved similarly for both groups. Results contribute to a growing body 
of work evaluating the impact of pharmacogenomics testing to inform antidepres-
sant medication treatment for depression and anxiety, and provides important initial 
evidence for the role of pharmacists in care delivery. Pharmacogenomic testing may 
be a valuable tool to allow pharmacists to more effectively collaborate in facilitating 
clinical treatment decisions. ClinicalTrials.gov registration: (NCT03591224).
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Findings are mixed on whether pharmacogenomic testing as a tool to guide antide-
pressant treatment improves depression response, remission, and symptom severity.
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INTRODUCTION
Antidepressant medication represents a first- line treatment for 
many depressive and anxiety disorders, including major depres-
sive disorder (MDD)1 and generalized anxiety disorder (GAD).2 
A high proportion of patients seeking treatment for depression 
are treated with antidepressant medication, frequently within 
primary care settings.3,4 Yet, antidepressant treatment is recog-
nized to produce modest remission rates in depression.5 Indeed, 
antidepressants are linked to suboptimal rates of response6,7 and 
a substantial percentage of patients do not achieve remission de-
spite several trials of antidepressant medication.5,8,9 Emergent 
adverse events from antidepressant use present a further chal-
lenge, reducing treatment tolerability and adherence.10,11
The literature on pharmacogenomics as a tool to support 
antidepressant precision is burgeoning. Patient response to an-
tidepressant medication is proposed to be a polygenic trait, with 
common genetic variants accounting for a sizable proportion 
(over 40%) of the variability in response.12 Indeed, the genes en-
coding for cytochrome P450 (CYP450), a family of hepatic en-
zymes involved in the metabolism of antidepressant medications, 
are highly polymorphic and have therefore been a major focus of 
psychiatric pharmacogenomic research.13 Previous reviews sug-
gest that functional variants in the CYP2D6 and CYP2C19 genes 
in particular produce phenotypes characterized by varying levels 
of activity of hepatic enzymes, which have been linked to param-
eters of antidepressant medication metabolism.13,14
Only a minority of available pharmacogenomic tests have 
been subject to empirical investigation in the form of random-
ized controlled trials (RCTs), nonrandomized case- control 
studies, and naturalistic, observational studies.15 Limitations 
of many existing investigations have been previously out-
lined,15,16 including small sample sizes, improper blinding 
procedures, nonrandomization, and retrospective designs. 
Findings from these investigations are equivocal with respect 
to whether pharmacogenomic testing improves depression re-
sponse, remission, and symptom severity.15– 17 Several, recent 
RCTs have failed to find a positive effect of pharmacogenetic 
treatment on their primary outcomes of symptom improve-
ment18,19 or patient- reported sustained response.20 On the 
other hand, recent meta- analyses have concluded that acute 
treatment for depression guided by pharmacogenetic testing 
improved response and remission relative to treatment as 
usual (TAU),17 with testing associated with 1.71 greater like-
lihood of symptom remission following acute treatment.21
Evidently, further investigation is needed to more accu-
rately assess treatment response and tolerability in response 
to pharmacogenomic guided treatment.17 Studies that aim to 
approximate treatment of depression as it occurs in the real- 
world are crucial to build support for the generalizability of 
positive results. For example, there is support that primary care 
practitioners are consulted more widely than psychiatrists by 
patients for mental health issues.22,23 Relatedly, primary care 
physicians are also noted to prescribe more antidepressant 
medications relative to psychiatrists.24 Tanner and colleagues 
reported that in their naturalistic investigation, improvement 
in depression severity following testing was seen in patients 
treated in both primary care and psychiatric settings.22
Recently, a more active role has been argued for phar-
macists in pharmacogenomic testing.25 Pharmacists may be 
ideally positioned to interpret pharmacogenomic testing pro-
files and provide recommendations, owing to their special-
ized training in pharmacology.25– 27 Indeed, previous research 
suggests that involvement of pharmacists in depression man-
agement, including through patient education and counsel-
ling, can improve adherence to antidepressant medications.27 
Moreover, recent work leveraging prescription dispensing 
data in community pharmacies in the Netherlands estimated 
that approximately one out of four new prescriptions of 
common primary care medications will have an actionable 
gene- drug interaction,28 highlighting the potential impact of 
pharmacogenomic testing in this setting.
In our earlier observational investigation within commu-
nity pharmacies, pharmacogenomic testing by pharmacists 
WHAT QUESTION DID THIS STUDY ADDRESS?
We evaluated the impact of pharmacogenomics guided versus standard antidepres-
sant treatment of depression and anxiety as they occur in the real- world, implemented 
by pharmacists in three large community pharmacies.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Results from this study provide initial evidence in support of a pharmacist- led phar-
macogenomic testing program in the treatment of mental health difficulties, as well as 
evidence for the role of pharmacists in care delivery.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
In supporting the external validity of pharmacogenomic testing, this study has im-
plications for how primary care clinicians may manage antidepressant medication 
use in their patients. In conjunction with measurement- based care, pharmacogenomic 
testing may help pharmacists more confidently and effectively manage patients in a 
protocolized and evidence- based manner.
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was associated with the successful identification of clinically 
significant drug therapy problems.26 In an open label RCT, 
pharmacist- led pharmacogenomic testing in a home health 
sample with a range of health problems was associated with 
a reduced number of re- hospitalizations and emergency de-
partment visits relative to TAU.29 Relevant to the present 
study, a retrospective evaluation of pharmacist facilitated 
pharmacogenomic testing in depressed inpatients was linked 
to shorter hospital stays compared to an untested cohort.30 
Taken together, such results provide important support for 
the feasibility and potential impact of pharmacist- led phar-
macogenomic testing for medication optimization.
Our study aimed to extend the research on pharmacist- led 
pharmacogenomic testing in the treatment of mental health 
difficulties with an RCT design. Specifically, we evaluated the 
impact of pharmacogenomics guided versus standard antide-
pressant treatment of depression and anxiety, as implemented 
by pharmacists in three large community pharmacies. The 
impact of testing on the identification of drug therapy prob-
lems, and on the short- term and long- term patient- reported 
outcomes (PROs) of depression, anxiety, disability, and treat-
ment satisfaction were assessed, in keeping with recent calls 
to incorporate PROs in psychiatry outcome research.17 We 
hypothesized that participants randomized to the experimen-
tal group (pharmacogenomics guided treatment) would report 
greater improvements in PROs compared to those randomized 
to the control group (TAU) over a 6- month period.
METHODS
Participants
This protocol was reviewed and approved by an accredited, 
independent ethics board and was conducted in accordance 
with the Declaration of Helsinki of 1975. Participants con-
sisted of 213 outpatients (159 women, 53 men, and 1 did 
not report), ranging in age from 18 to 77 years (M = 42.69, 
SD  =  14.90). Participants were from two urban commu-
nity pharmacies in Toronto, Ontario, and a third location in 
Oakville, Ontario. All participants met the following inclu-
sion criteria: (1) age 18 years or older; (2) prescribed one 
or more antidepressants; (3) diagnosed with MDD and / 
or GAD; (4) newly initiated on antidepressant therapy or 
a recent change in therapy; (5) experiencing adverse drug 
reactions, suboptimal response, or dissatisfaction with 
antidepressant therapy; and (6) demonstrated dissatisfac-
tion based on the Treatment Satisfaction with Medicines 
questionnaire (SATMED- Q). Participants were excluded 
from the study if they: (1) had a poor command of English 
or were unable to provide fully informed consent; (2) had 
received a liver transplant (as a buccal swab will not de-
tect liver DNA); (3) were nonadherent to prescribed drug 
therapy due to other failure or refusal to take medication 
as prescribed (nonmedical influencing factors); and (4) 
were diagnosed with schizophrenia, bipolar disorder, or 
dementia.
Measures
All outcome measures were administered at baseline, and at 
months 1, 3, and 6. Depression was assessed using the Patient 
Health Questionnaire (PHQ- 9),31 a nine- item self- report 
questionnaire with a total score of 5, 10, and 15 indicating 
mild, moderate, and severe symptoms, respectively.
GAD symptom severity was assessed using the 7- item 
self- report, GAD- 732; total score cutoffs of 5, 10, and 15 sim-
ilarly indicate mild, moderate, and moderately severe anxiety, 
respectively. The Sheehan Disability Scale (SDS),33 a three- 
item self- report questionnaire was used to assess functional 
disability and impairment. Treatment satisfaction was ascer-
tained using the SATMED- Q,34 a 17- item self- report ques-
tionnaire assessing side effects, drug efficacy, convenience 
of use, impact on activities of daily living, medical care, and 
general satisfaction. Internal consistencies of all measures 
were acceptable according to established cutoffs: PHQ- 9 
α = 0.85– 0.91; GAD- 7 α = 0.91; SDS α = 0.84– 0.95; and 
SATMED- Q α = 0.82– 0.88.
Procedures
Pharmacists reviewed the pharmacy patient database to 
identify patients who had been prescribed antidepressants 
and who may have been dissatisfied with their therapy, 
identified based on the frequency of or recent changes in 
their medication, dosage, or documented evidence of non-
compliance. Walk- in patients using antidepressants who 
met study criteria were also provided the opportunity to 
participate. Following initial identification of potential par-
ticipants, patients were prescreened using the SATMED- Q 
to establish eligibility. Patients who scored greater than 2 
on select items (1– 3) and/or less than  2 on others (4– 9) 
were considered to be dissatisfied with their current drug 
therapy and would benefit from pharmacogenetics screen-
ing. All patients who met the remaining eligibility crite-
ria were invited to participate upon consent and received 
the Pillcheck test, available through GeneYouIn, Inc. in 
Canada. The Pillcheck test was developed for integration 
into a clinical pharmacy setting and provides a compre-
hensive report based on variation in 19 genes, with im-
plications for over 200 nonpsychotropic and psychotropic 
medications, including antidepressant medications (see 
Table S1).35 Recommendations generated by the Pillcheck 
test are aligned with existing clinical guidelines (i.e., the 
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Clinical Pharmacogenetics Implementation Consortium 
[CPIC])36 and regulatory bodies (i.e., labeling guidelines 
of the US Food and Drug Administration [FDA]).26
The Pillcheck report prioritizes the CPIC guidelines 
for medications with both FDA and CPIC guidelines be-
cause the latter has more refined recommendations for spe-
cific diplotypes. There are a limited number of drugs with 
Pharmacogenomics Knowledgebase (PharmGKB) evidence 
(levels 1 and 2), which are deemed clinically significant by 
independent expert pharmacists, that are also included in 
the Pillcheck report. The recommendations are constructed 
by expert clinicians based on the review of publications an-
notated by the PharmGKB database. The functional anno-
tation of an enzyme’s activity (i.e., classification of specific 
diplotypes to poor, intermediate, or normal metabolizer sta-
tus) is aligned according to the CPIC guidelines for other 
drugs metabolized by the same enzyme. The Pillcheck re-
ports are updated annually to reflect revisions to the CPIC 
guidelines and new FDA drug labels. The Pillcheck version 
2.1.0 report that was used throughout the study period, 
reported according to the CPIC guidelines and the FDA 
drug labels published before January 2018. For example, 
CYP2C19*1/17 was classified as a rapid metabolizer and 
CYP2D6 *1/*4 was classified as a normal metabolizer. The 
Pillcheck test has been linked to the successful identifica-
tion of drug therapy problems in community pharmacy26 
and nursing home37 settings.
Prior to the study, pharmacists completed an online phar-
macogenetics overview course provided through GeneYouIn, 
and over 8 h of hands- on training, including an introduction to 
CPIC guidelines and report interpretation. Recommendations 
were based on the integration of patient drug profiles and full 
medical history with the Pillcheck report.
A prospective, single- blind randomized controlled design 
was used. Participants were randomly assigned to either the 
pharmacogenomics guided group (n = 105) or control group 
(n = 108) based on a random sequence generated by an online 
randomizer tool, which only the Principal Investigator had 
access to. Participant profiles were created on the Pillcheck 
portal and the pharmacists facilitated the Pillcheck registra-
tion and supervised the buccal swab DNA collection process. 
For participants in the pharmacogenomics guided group, 
pharmacists received the Pillcheck report 2 weeks following 
swab collection; this report guided recommendations for op-
timizing antidepressant drug therapy either through dose ad-
justment or a change in drug therapy. For participants in the 
control group, recommendations were made as per standard 
of care clinical guidelines. Changes in therapy were discussed 
with participants in both study groups; however, participants 
were blinded to their group assignment. The pharmacist 
communicated recommended changes with the prescriber 
in both study groups via fax or telephone; prescribers were 
able to accept, decline, or disregard these recommendations. 
Prescribers were asked to maintain the integrity of the study 
by withholding knowledge of the pharmacogenomics re-
sults and study group assessment until the end of the study. 
Pillcheck results were not communicated to participants until 
the end of the study.
Statistical analyses
Mixed effect models were conducted on the full data. The 
PHQ- 9 total score served as the primary outcome variable, 
and the GAD- 7, SDS, and SATMED- Q total scores served 
as secondary outcomes, in separate models. Time was en-
tered as within- subject categorical factor with four levels, 
and study group as between- subject factor with two lev-
els, as well as their interaction. Mixed effect models have 
been applied in recent investigations of pharmacogenomics 
guided treatment.19 This analysis approach handles miss-
ing values using maximum likelihood estimation, which is 
able to use all available information in all recruited partici-
pants, and is associated with the least bias in a comparison 
of methods for dealing with missing data.38 We followed 
the intention- to- treat principle and analyzed all rand-
omized participants. In line with recommendations,39 we 
conducted models with and without the inclusion of impor-
tant covariates, including age and sex, pharmacy site, pre-
scriber (family physician, specialist, family physician and 
specialist, and nurse practitioner), and method of payment 
(third party, provincial drug coverage, or cash). We also 
conducted sensitivity analyses, restricted to participants in 
the pharmacogenomics guided group whose prescribers ac-




Participants were recruited between April 2018 and May 
2019, with the follow- up period ending December 2019. 
Participants exhibited the following current diagnoses: MDD 
(n = 169), GAD (n = 165), and other disorders (e.g., anxi-
ety or eating disorders; n = 10); the majority of participants 
(n = 133) met criteria for more than one current psychiat-
ric diagnosis, with most exhibiting both MDD and GAD 
(n = 124). There were no differences across study groups in 
sex (χ2 = 1.13, p = 0.57) or age (t = 0.77, p = 0.44).
Descriptive statistics for participant demographic and 
clinical features at baseline are presented in Table 1. There 
were no differences in the primary outcome (PHQ- 9) at 
baseline across study groups; there were similarly no differ-
ences in two secondary outcomes (GAD- 7 and SDS). The 
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SATMED- Q was greater in the pharmacogenomics guided 
group at baseline, with a small effect size (d = 0.28). Skew 
and kurtosis of all outcomes were below established cutoffs.
Attrition in the pharmacogenomics guided arm and con-
trol arm was 16 in each group. Reasons for loss included dis-
continuation of medication (n = 11), participant withdrawal 
(n = 12), and lost to follow- up (n = 9; see Figure S1). Of 
the 213 participants who completed measures at baseline, 
197 completed measures at month 1, 187 at month 3, and 
182 at month 6. Family physicians prescribed medication 
for the majority of participants (n  =  153), although fam-
ily physicians and specialists (n = 14), specialists (n = 41), 
and nurse practitioners (n = 5) also prescribed medications 
as well. Medication costs were paid by third parties (i.e., 
insurance; n  =  113), provincial drug programs (n  =  69), 
or participants (n = 30). Medications prescribed through-
out the study in the intent- to- treat sample can be found in 
Table S2.
Effect of treatment group on study outcomes
Intent- to- treat analyses
All study outcomes exhibited significant effects of time, and 
the GAD- 7 exhibited a significant effect of treatment; these 
main effects were moderated by a time by group interaction 
for three of four outcomes (see Table 2). More specifically, 
the primary outcome (PHQ- 9) and two secondary outcomes 
(GAD- 7 and SDS) exhibited significant time by group in-
teractions indicating that they improved for participants 
who received pharmacogenomics guided treatment more 
so than they did for participants who received TAU. The 
SATMED- Q did not exhibit such a differential improvement 
across study groups over time, indicating that treatment sat-
isfaction improved similarly for both groups from baseline to 
month 6 (see Figure 1). Models including covariates demon-







t (p)M (SD) M (SD) M (SD)
Age 42.69 (14.90) 43.46 (15.26) 41.90 (14.55) 0.77 (0.44)
Female (%)a 159 (74.65) 82 (75.93) 77 (73.33) 1.13 (0.57)
GAD- 7 11.67 (5.54) 11.57 (5.70) 11.76 (5.93) 0.24 (0.81)
PHQ- 9 13.86 (6.17) 14.18 (6.31) 13.52 (6.04) 0.78 (0.43)
SATMED- Q 35.16 (10.24) 33.77 (10.34) 36.59 (9.99) 2.02 (0.04)
SDS 17.37 (7.39) 17.04 (7.64) 17.72 (7.14) 0.67 (0.50)
Payment:
Third party 113 54 59
Provincial drug coverage 69 38 31
Participants 30 16 14
Prescriber:
Family physician 153 74 79
Family physician and 
specialist
14 10 4
Specialist 41 20 21
Nurse practitioner 5 4 1
Prescriptionsb :
SSRIs 166 83 83
SNRIs 72 31 41
TCAs 7 5 2
Antipsychotics 32 20 12
Other antidepressants 86 46 40
Abbreviations: GAD- 7, Generalized Anxiety Disorder 7; M, mean; PGx, pharmacogenomics; PHQ- 9, Patient 
Health Questionnaire 9; SATMED- Q, Treatment Satisfaction with Medicines Questionnaire; SD, standard 
deviation; SDS, Sheehan Disability Scale; SNRIs, serotonin and norepinephrine reuptake inhibitors; SSRIs, 
selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
aSignifies that study group differences in sex evaluated via c2. 
bSignifies total number of prescriptions throughout the study, including at baseline. 
T A B L E  1  Participant demographic and 
clinical features at baseline
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demonstrated significant effects across all outcomes, such 
that younger age was associated with better outcomes.
Sensitivity analyses
Sensitivity analyses were conducted, and restricted to those 
participants in the pharmacogenomics guided group whose 
prescribers accepted pharmacist recommendations (n = 79; 
see Table  2). Again, all study outcomes exhibited signifi-
cant effects of time, and now the PHQ- 9 and GAD- 7 further 
exhibited significant effects of treatment. Again, the PHQ- 
9, GAD- 7, and SDS demonstrated significant time × group 
interactions, demonstrating greater improvements for par-
ticipants receiving pharmacogenomics guided treatment than 
TAU for these outcomes. Again, treatment satisfaction did 
not demonstrate such an interaction, exhibiting similar im-
provements across both study groups. Notably, prescriber 
acceptance of pharmacist recommendations differed across 
the study groups (χ2  =  11.64, p  =  0.001), with 75.2% ac-
ceptance in the pharmacogenomics guided group and 52.8% 
in the control group. Sensitivity analyses were therefore re-
peated, and restricted to participants whose prescribers ac-
cepted pharmacist recommendations in both groups (79 and 
57 participants in the pharmacogenomics guided and control 
groups, respectively). All significant time × group interac-
tions were replicated (see Table S4).
Accepted recommendations included dose adjustments 
(e.g., pharmacist recommended increased dosage due to ultr-
arapid metabolism, resulting in suboptimal response; n = 72 
in pharmacogenomics guided group vs. n  =  50 in control 
group), medication switches (e.g., pharmacist recommended 
switching to a different medication to manage adverse reac-
tions as a result of poor metabolism of original medication; 
n  =  26 in pharmacogenomics guided group vs. n  =  16 in 
control group), addition of a new medication (e.g., pharma-
cist recommended an adjunctive therapy; n = 10 in pharma-
cogenomics guided group vs. n = 2 in control group), and 
medication adherence (e.g., pharmacist recommended that 
patient continue with medication regimen; n  =  5 in phar-
macogenomics guided group vs. n  =  6 in control group). 
Recommendations were made for the majority of participants 
T A B L E  2  Primary and secondary outcomes: mixed effects models
ITT analyses Sensitivity analyses
Time Group Time * group Time Group Time * group
F (p) F (p) F (p) F (p) F (p) F (p)
GAD- 7 30.94 (<0.001) 4.26 (0.04) 4.17 (0.01) 30.75 (<0.001) 7.23 (0.01) 4.93 (0.002)
PHQ- 9 23.65 (<0.001) 2.06 (0.15) 2.74 (0.04) 23.16 (<0.001) 8.50 (0.004) 2.92 (0.03)
SATMED- Q 33.14 (<0.001) 1.07 (0.30) 0.11 (0.95) 31.95(<0.001) 6.55 (0.01) 0.23 (0.88)
SDS 33.01 (<0.001) 1.02 (0.31) 6.25 (<0.001) 33.13 (<0.001) 3.41 (0.07) 7.33(<0.001)
Abbreviations: F, F- statistic; GAD- 7, Generalized Anxiety Disorder 7; ITT, intention- to- treat; PHQ- 9, Patient Health Questionnaire 9; SATMED- Q, Treatment 
Satisfaction with Medicines Questionnaire; SDS, Sheehan Disability Scale.
F I G U R E  1  Clinical outcomes 
over time and study group. Note: PHQ- 
9 = Patient Health Questionnaire 9; 
GAD- 7 = Generalized Anxiety Disorder 
7; SDS = Sheehan Disability Scale; 
SATMED- Q = Treatment Satisfaction with 
Medicines Questionnaire; Mth = Month; 
PGx Guided = Pharmacogenomics guided 
treatment. Panels illustrate the marginal 
means and standard errors of control and 
PGx Guided group at baseline, months 1, 3, 
and 6 across all clinical outcomes
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(n = 204); although the number of recommendations per par-
ticipant ranged from one to five, most received one (n = 124) 
or two (n = 60). Pharmacist recommendations did not differ 
across study groups: there was no difference in the number 
of participants who received pharmacist recommendations 
(χ2 = 0.37, p = 0.54) or the number of pharmacist recom-
mendations made (χ2 = 1.57, p = 0.81) across study groups. 
Pharmacist recommendations were also more commonly ac-
cepted when medication costs were covered by third parties 
or provincial drug coverage (χ2=9.54, p = 0.02; see Figure 2). 
Prescriber acceptance of pharmacist recommendations did 
not differ across the pharmacy sites (χ2 = 0.29, p = 0.59) or 
by prescriber (χ2 = 1.53, p = 0.68).
DISCUSSION
Consistent with hypotheses, participants with MDD or GAD 
randomized to receive pharmacist- led pharmacogenom-
ics guided treatment reported greater improvements in de-
pression severity over a 6- month period compared to those 
randomized to receive TAU. Participants receiving pharma-
cogenomics guided treatment also reported greater improve-
ments in generalized anxiety and in disability over this period 
compared to those receiving TAU. Treatment satisfaction did 
not differ across groups, however. Significant results were 
not only statistically robust but also clinically meaningful. 
The overall change in PHQ- 9 total scores over 6 months was 
5.03 and 2.42 in the pharmacogenomics guided and control 
groups, respectively, representing improvements from base-
line depression severity of 36% versus 18%. Similarly, im-
provements in anxiety and disability were two times greater 
in the pharmacogenomics guided group versus the control 
group: GAD- 7 improved by 41% versus 23%, and SDS by 
44% versus 18% across these groups.
The current investigation responded to recent calls for the 
use of PROs in pharmacogenomics research, and has strong 
external validity due to use of these scales in measurement- 
based care in clinical settings. Yet, as prescribers were not 
blinded in our study, the possibility that participants were in-
advertently unblinded to group assignment, or that there were 
potential differences in treatment provided across arms,21 
cannot be overlooked. Thus, biases (e.g., expectancy bias 
and performance bias) may have influenced results. Blinding 
of participants, outcome assessors, as well as prescribers19 
would buoy these results in future replications. Notably, 
the current investigation did not find expected differences 
in treatment satisfaction across groups. Our capacity to de-
tect effects may have been impacted by a restricted range of 
scores, as the overall change demonstrated in this study is 
below the “minimum important difference” demonstrated for 
this measure.40 Future research might evaluate other domains 
and measures of patient satisfaction and experience, to more 
fully elucidate how this multifaceted outcome might differ 
across those who do and do not receive pharmacogenomics 
guided care.
The current investigation thus provides important support 
for the role of pharmacists in the implementation of phar-
macogenomic testing, and associated treatment recommen-
dations. Differential prescriber acceptance of pharmacist 
recommendations across study groups suggests that phar-
macogenomics test results may have increased confidence in 
these recommendations. Pharmacist- led pharmacogenomic 
testing leverages the specialized training of these allied 
health professionals, and may provide a promising method by 
which to scale this decision support tool. Pharmacogenomic 
testing by pharmacists has identified clinically significant 
drug therapy problems in previous research.26 The current 
investigation extends this foundation to the outpatient treat-
ment of mental health difficulties, using a robust prospective, 
single- blind randomized controlled design. Notably, differ-
ential prescriber acceptance of pharmacist recommendations 
across payment methods suggest that prescribers may be 
more inclined to consider these recommendations when the 
F I G U R E  2  Prescriber acceptance of 
pharmacist recommendations by payment 
type. Note: ODB = Ontario Drug Benefit 
program; TP = third party (i.e., insurance 
company). Figure illustrates the proportion 
of participants whose clinicians accepted 
pharmacist recommendations across 
remuneration type, or how medication costs 
were covered
1366 |   PAPASTERGIOU ET Al.
financial implications for their patients are minimized, and 
underscores the importance of tracking these important prac-
tical considerations in this research.
The present study was designed to improve overall partici-
pant therapeutic benefits, enabling pharmacists to flag poten-
tial gene- drug interactions and help pharmacists assess risk 
of drug- drug interactions in participants with reduced drug 
metabolism. Results contribute to a growing body of work 
evaluating the impact of pharmacogenomics testing to inform 
antidepressant medication treatment of depression and anx-
iety, and provides important initial evidence for the role of 
pharmacists in care delivery. Pharmacogenomic testing may 
be a valuable tool to allow pharmacists to more effectively 
collaborate in facilitating clinical treatment decisions. As 
pharmacists’ role and scope expand to include changing dos-
ages to initiating prescription therapies (depending on geo-
graphical region), evidence- based decision making becomes 
even more critical. Unfortunately, due to the complexity in 
managing psychiatric conditions and uncertainties in treat-
ment guidelines, pharmacists are often reluctant to intervene 
on any identified drug therapy problems. Pharmacogenomic 
testing in conjunction with measurement- based care, includ-
ing validated patient- report scales may help pharmacists to 
more confidently and effectively manage patients in a proto-
colized and evidence- based manner. With the pharmacist’s 
skillset in both pharmacology and therapeutics, interpreting 
pharmacogenomic test results and developing an action plan 
is uniquely best- suited for pharmacists. Pharmacists may be 
particularly well- situated to identify those who may benefit 
from pharmacogenomic testing due to their high number of 
patient interactions each day, access to patients’ drug history, 
and detect reasons of noncompliance, such as adverse drug 
reactions.
The current investigation boasts numerous strengths. First, 
this study was characterized by high external validity or gen-
eralizability: experimental controls were minimized to permit 
an investigation of the closest approximation of a real- world 
implementation of pharmacist- led pharmacogenomics guided 
treatment possible. Eligibility criteria permitted the recruitment 
of a range of outpatients with depression and anxiety, heteroge-
neous in their prescriber, payment method, and other important 
features. Prescribers were free to follow pharmacist recommen-
dations or not, in line with current practice, and widely used 
brief measures of clinical outcomes were used. Second, partic-
ipant attrition was fairly limited at only 15%, maintaining the 
power to detect effects over a 6- month follow- up period and 
demonstrating the feasibility of this approach. Third, results 
were robust to the inclusion of covariates, and were replicated 
across both intent- to- treat and sensitivity analyses. Finally, by 
exploring sustained improvements in antidepressant treatment 
outcomes specific to guided therapy over a 6- month period, our 
study addresses a gap in the existing pharmacogenomic litera-
ture of studies investigating longer- term depression outcomes.19
Limitations
Nevertheless, several limitations are important to note. First, 
this study did not include blinded outcomes of the assessors or 
prescribers, which does introduce a risk of bias. Although we 
are not able to rule out issues associated with blinding, there 
were no differences in pharmacist recommendations across the 
study groups. However, this study lacked the power to com-
pare the kinds of recommendations made (e.g., medication 
switches, dose adjustments, and medication augmentations), 
precluding the ability to evaluate whether these differed sys-
tematically in a way that might have contributed to unblind-
ing. A fulsome demographic and clinical characterization of 
participants, using clinician- rated semistructured instruments, 
for example, was not possible, precluding the evaluation of 
potential covariates or moderators of effects. In line with gen-
der and sex differences in the prevalence of depression and 
anxiety,41,42 a greater number of women participated in this 
research; although sex was incorporated in covariate analyses, 
we lacked the power to examine sex as a predictor in its own 
right, including as a potential moderator of effects. Relatedly, 
participants’ history of medication exposure— a potentially 
important moderator of the effect of pharmacogenomic test-
ing in depression— was not formally collected in this study. 
Although this study is characterized by high external valid-
ity in many respects, the repeated administration of outcome 
measures and the 6- month follow- up period is not currently 
a standard of care uniformly implemented across pharmacy 
settings, and these features may have had therapeutic benefits 
in their own right. Further, this study was conducted at urban 
pharmacies, which may not generalize to pharmacies in other 
communities and settings. Finally, the Pillcheck did not detect 
all DNA variations that may have altered gene activity. Only 
specified genetic variations in White patients and major ethnic 
minority groups were tested.
CONCLUSION
To conclude, the current investigation provides initial evi-
dence in support of a pharmacist- led pharmacogenomic test-
ing program in the treatment of mental health difficulties. 
Results contribute to a growing body of work evaluating the 
impact of pharmacogenomics testing to inform antidepres-
sant medication treatment of depression and anxiety, and 
provide important initial evidence for the role of pharma-
cists in care delivery. Results suggest that pharmacogenomic 
testing may be a promising avenue to increase the ability 
of pharmacists to be actively involved in patient care and 
provide evidence- based and personalized insights regard-
ing patient- predicted treatment response, thereby empha-
sizing the importance of pharmacist- patient communication 
and interaction. Continued investigation into the benefits of 
   | 1367
PHARMACOGENOMICS GUIDED VERSUS STANDARD TREATMENT: A RANDOMIZED 
CONTROLLED TRIAL
pharmacogenomics guided pharmacotherapy therapy, in-
cluding healthcare economics analysis and important mod-
erators of effects, is warranted.
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